维生素D与子宫肌瘤生长、发生和消失:一项前瞻性超声研究
该前瞻性社区队列研究纳入1610名23-35岁无既往肌瘤临床诊断的非裔美国女性,随访5年。血清25(OH)D≥20ng/mL相比<20ng/mL与肌瘤生长减少9.7%相关(95%CI:-17.3%,-1.3%)。结论支持高浓度维生素D减少肌瘤发展的假说,但受限于25(OH)D≥30ng/mL参与者较少。
要点
- 血清25(OH)D≥20ng/mL相比<20ng/mL与肌瘤生长减少9.7%相关(95%CI:-17.3%,-1.3%)。
- 血清25(OH)D≥30ng/mL相比<30ng/mL与肌瘤发生风险降低相关但未达统计学显著(校正HR=0.78;95%CI:0.47,1.30)。
- 血清25(OH)D>30ng/mL组肌瘤消失增加32%(校正RR=1.32;95%CI:0.95,1.83),未达统计学显著。
核心结论
- 数据支持高浓度维生素D减少肌瘤发展的假说,但受限于25(OH)D≥30ng/mL参与者较少。
- 需要干预试验提高并维持25(OH)D浓度>30ng/mL后前瞻性监测肌瘤发展,以进一步评估补充维生素D的疗效并确定最佳治疗方案。
研究设计与样本
- 前瞻性社区队列研究,入组时间2010-2012年,共4次研究访视,历时5年,进行标准化超声检查、测量25-羟基维生素D(25(OH)D)并更新协变量。
- 研究地点为密歇根州底特律地区;研究对象为入组时23-35岁、自我认同为非裔美国或黑人女性、无既往肌瘤临床诊断者。
- 血清25(OH)D采用免疫分析法或液相色谱-串联质谱法测量。
- 主要结局为肌瘤生长(以每18个月对数体积变化衡量)和肌瘤发生(既往无肌瘤子宫中首次检出肌瘤);次要结局为肌瘤消失(访视间肌瘤数量减少)。
- 生长估计采用线性混合模型并转换为高 vs 低25(OH)D的估计体积差异;发生差异采用年龄特异性Cox回归估计风险比;肌瘤消失采用Poisson回归建模;协变量(生殖和激素变量、人口学特征、体重指数、当前吸烟)和25(OH)D均作为时变因素建模。
主要发现
- 入组时1610名有至少1次随访超声的参与者中,平均年龄29.2岁,73%维生素D缺乏(<20ng/mL),仅7%维生素D充足(≥30ng/mL)。
- 血清25(OH)D≥20ng/mL相比<20ng/mL与肌瘤生长估计减少9.7%相关(95%CI:-17.3%,-1.3%),与最小校正估计值-8.4%(95%CI:-16.4,0.3)相似。
- 血清25(OH)D≥30ng/mL相比<30ng/mL与肌瘤发生不精确的22%降低相关(校正HR=0.78;95%CI:0.47,1.30),与未校正估计值0.84(95%CI:0.51,1.39)相似。
- 血清25(OH)D>30ng/mL组肌瘤消失增加32%(校正RR=1.32;95%CI:0.95,1.83)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为需要干预试验提高并维持25(OH)D浓度>30ng/mL后前瞻性监测肌瘤发展,以进一步评估补充维生素D的疗效并确定最佳治疗方案。
局限性
- 受限于25(OH)D≥30ng/mL参与者较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Fibroid treatments that have few side-effects and can preserve fertility are a clinical priority. We studied the association between serum vitamin D and uterine fibroid growth, incidence, and loss. DESIGN: A prospective community cohort study (enrollment 2010-2012) with 4 study visits over 5 years to conduct standardized ultrasounds, measure 25-hydroxyvitamin D (25(OH)D), and update covariates. SETTING: Detroit, Michigan area. PATIENTS: Self-identified African American or Black women aged 23-35 at enrollment without previous clinical diagnosis of fibroids. INTERVENTION(S): Serum 25(OH)D measured using immunoassay or liquid chromatography-tandem mass spectrometry. MAIN OUTCOME MEASURE(S): The primary outcomes were fibroid growth, as measured by change in log volume per 18 months, and fibroid incidence (first detection of fibroid in previously fibroid-free uterus). Adjusted growth estimates from linear mixed models were converted to estimated difference in volume for high vs. low 25(OH)D. Incidence differences were estimated as hazard ratios from age-specific Cox regression. A secondary outcome fibroid loss (reduction in fibroid number between visits), was modeled using Poisson regression. Covariates (reproductive and hormonal variables, demographics, body mass index, current smoking) and 25(OH)D were modeled as time-varying factors. RESULT(S): At enrollment among 1,610 participants with ≥1 follow-up ultrasound, mean age was 29.2 years, 73% had deficient vitamin D (<20ng/mL), and only 7% had sufficient vitamin D (≥30ng/mL). Serum 25(OH)D ≥20ng/mL compared with <20ng/mL was associated with an estimated 9.7% reduction in fibroid growth (95% confidence interval [CI]: -17.3%, -1.3%), similar to the minimally adjusted estimate -8.4% (95% CI: -16.4, 0.3). Serum 25(OH)D ≥30ng/mL compared with <30ng/mL was associated with an imprecise 22% reduction in incidence (adjusted hazard ratio=0.78; 95% CI: 0.47, 1.30), similar to the unadjusted estimate of 0.84 (95% CI: 0.51, 1.39). The >30ng/mL group also had a 32% increase in fibroid loss (adjusted risk ratio=1.32; 95% CI: 0.95, 1.83). CONCLUSION(S): Our data support the hypothesis that high concentrations of vitamin D decrease fibroid development but are limited by the few participants with serum 25(OH)D ≥30ng/mL. Interventional trials that raise and maintain 25(OH)D concentrations >30ng/mL and then prospectively monitor fibroid development are needed to further assess supplemental vitamin D efficacy and determine optimal treatment protocols.
引用
- Harmon QE, Patchel SA, Denslow S, et al. Vitamin D and uterine fibroid growth, incidence, and loss: a prospective ultrasound study. Fertil Steril. 2022. PMID: 36150919. doi:10.1016/j.fertnstert.2022.08.851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。